- Reference code :
- wf399
- Published date :
-
09 October 2001
- Expired date :
-
24 February 2029
Stanhope Gate, London, UK - The long-awaited results of head-to-head clinical trials between AstraZeneca’s newest proton pump inhibitor (PPI) therapy, Nexium® (esomeprazole), and its principal competitor, lansoprazole, were released today at the United European Gastroenterology Week (UEGW) in Amsterdam.
-
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 07:01 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
